{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Medico Remedies Ltd
Why is Medico Remedies Ltd falling/rising?
As of 09 January, Medico Remedies Ltd’s stock price has experienced a notable decline, reflecting a combination of recent market pressures and investor behaviour despite the company’s underlying operational strengths.
Medico Remedies Downgraded to Hold Amid Mixed Technicals and Valuation Concerns
Medico Remedies Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 30 December 2025. This adjustment reflects a nuanced reassessment across quality, valuation, financial trends, and technical indicators, signalling a more cautious stance despite the company’s solid financial performance and operational strengths.
Medico Remedies Ltd is Rated Buy
Medico Remedies Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 24 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the most up-to-date view of the company’s fundamentals, returns, and technical outlook.
Medico Remedies Hits Upper Circuit Amid Strong Buying Pressure and Robust Trading Activity
Medico Remedies Ltd witnessed a significant surge in its share price on 23 Dec 2025, hitting the upper circuit limit of 10%, reflecting intense buying interest and robust market participation. The stock outperformed its sector and broader indices, signalling heightened investor enthusiasm in this micro-cap pharmaceutical player.
Medico Remedies: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals
Medico Remedies, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment following a detailed evaluation of its quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent changes in the company’s analytical perspective, providing investors with a comprehensive understanding of its current standing.
Medico Remedies Sees Shift in Market Assessment Amid Strong Financial and Technical Signals
Medico Remedies, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation, reflecting a combination of robust financial results and evolving technical indicators. This shift highlights the company's recent performance across quality, valuation, financial trends, and technical parameters, offering investors a comprehensive view of its current standing.
How has been the historical performance of Medico Remedies?
Medico Remedies has shown consistent growth in net sales and profits, with net sales increasing from 121.02 Cr in Mar'22 to 150.94 Cr in Mar'25, and operating profit rising from 7.21 Cr to 15.00 Cr during the same period. The company's total assets also expanded significantly, reflecting a robust financial performance.
Medico Remedies Sees Revision in Market Evaluation Amidst Mixed Financial Signals
Medico Remedies, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, offering investors a refreshed perspective on its market position.
Medico Remedies Forms Golden Cross, Signalling Potential Bullish Breakout
Medico Remedies, a player in the Pharmaceuticals & Biotechnology sector, has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average crosses above the 200-day moving average. This development often signals a potential shift towards a bullish trend and long-term momentum in the stock’s price movement.
Is Medico Remedies overvalued or undervalued?
As of November 27, 2025, Medico Remedies is considered overvalued with a PE ratio of 37.29, a Price to Book Value of 6.33, and an EV to EBITDA of 28.31, indicating high valuations relative to earnings and assets, despite having a lower PE than Sun Pharma and a higher PEG ratio of 0.78 compared to its peers.
How has been the historical performance of Medico Remedies?
Medico Remedies has shown consistent growth in net sales and profits, with net sales increasing from 97.69 Cr in Mar'19 to 150.94 Cr in Mar'25, and profit after tax rising to 10.09 Cr in Mar'25. The company has also improved its operating profit and cash flow, indicating enhanced operational efficiency.
Medico Remedies Shows Strong Financial Growth Amidst Stakeholder Confidence Concerns
Medico Remedies, a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its evaluation, indicating a shift in market sentiment. The company reported strong financial metrics, including a low Debt to EBITDA ratio and significant growth in operating profit and net sales, despite facing some challenges with promoter confidence.
How has been the historical performance of Medico Remedies?
Medico Remedies has shown consistent growth in net sales and profitability, with net sales increasing from 97.69 Cr in Mar'19 to 150.94 Cr in Mar'25, and profit after tax rising from 1.57 Cr to 10.09 Cr during the same period, reflecting improved operational efficiency and a growing profitability margin. Total assets also expanded significantly, indicating a robust financial trajectory.
Why is Medico Remedies falling/rising?
As of 10-Nov, Medico Remedies Ltd's stock price is Rs 51.50, up 3.1% today, reversing a two-day decline. Despite recent gains, the stock has underperformed over the past year, raising concerns about its valuation and future prospects.
When is the next results date for Medico Remedies?
The next results date for Medico Remedies is 13 November 2025.
Medico Remedies Faces Mixed Performance Amid Profit Growth and Stake Reduction Concerns
Medico Remedies, a microcap in the Pharmaceuticals & Biotechnology sector, has seen a recent adjustment in its evaluation score, reflecting a shift in technical trends. Despite a negative return over the past year, the company reported a significant profit increase and maintains a strong capacity to service its debt.
How has been the historical performance of Medico Remedies?
Medico Remedies has shown consistent growth in net sales and profits, with net sales increasing from 121.02 Cr in March 2022 to 150.94 Cr in March 2025, and profit after tax reaching 10.09 Cr. The company also reported improved operating profit and a strengthening balance sheet, indicating a robust performance trajectory.
Medico Remedies Adjusts Evaluation Amid Mixed Performance Indicators and Stakeholder Confidence Shift
Medico Remedies, a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its evaluation, indicating a shift in market sentiment. The company has shown strong financial performance, with significant growth in net sales and operating profit, despite a slight decline in promoter confidence.
How has been the historical performance of Medico Remedies?
Medico Remedies has shown consistent growth in net sales and profitability, with net sales increasing from 97.69 Cr in Mar'19 to 150.94 Cr in Mar'25, and profit after tax rising from 1.57 Cr to 10.09 Cr during the same period, indicating strong operational efficiency and financial performance. Total assets and liabilities have also expanded proportionally, reflecting overall positive financial trends.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
